Objective: The goal of this study was to assess oral penicillin response to Group B Streptococcus GBS in patients with symptomatic recurrent vulvovaginal colonization (SRVI) was designed. Methods: This study received approval from an internal review board. In patients with symptomatic recurrent vulvovaginal infections SRVI were screened for GBS, and GBS prevalence and penicillin response were assessed. A retrospective review of adults with SRVI was then performed in which GBS was cultured and all patients who had positive results received oral penicillin. Response was evaluated by symptoms and culture. Results: Of the 220 patients included, 22.3% were GBS-positive; 24.6% responded to one treatment, 20.1% required two treatments, 38.9% required three treatments; and 16.4% were unresponsive. GBS colonization was 22.3 %. Antibiotic response was 24.6% after one treatment and 55.3% of patients required three treatments; they were nonresponders and remained symptomatic. Conclusions: Screening for GBS in this population could be useful. ( J GYNECOL SURG 27:241)